[Value of Purple Sign for Predicting Rebleeding Events in Cirrhotic Patients Following Endoscopic Selective Varices Devascularization]

Overview

Journal Nan Fang Yi Ke Da Xue Xue Bao

Specialty General Medicine

Date 2022 Jan 11

PMID 35012914

Authors

Y Wu

M Chen

M Huang

G Liao

S Tang

H Zheng

Y Li

B Peng

X Zheng

S Pan

J Hou

B Chen

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the value of the purple sign for predicting long-term rebleeding events in cirrhotic patients following endoscopic selective varices devascularization.

Methods: We retrospectively analyzed the clinical data of 97 patients with liver cirrhosis, who had a history of gastroesophageal variceal bleeding and underwent endoscopic selective varices devascularization. Thirty-two of the patients showed purple sign after endoscopic treatment. We used propensity score matching (PSM) to minimize the selection bias of the patients (purple sign vs no purple sign) and reduce the intergroup differences of clinical characteristics. The primary outcome measure of this study was cumulative rebleeding events after endoscopic selective varices devascularization.

Results: The 1-year rebleeding rate (27.0% 36.7%) or 6-month rebleeding rate (10.9% 26.9%) following endoscopic treatment was not significantly different between the purple sign group and no purple sign group before PSM (=0.2385). But after PSM, the 1-year rebleeding rate (28.2% 56.4%) and 6-month rebleeding rate (5.0% 37.0%) were significantly lower in the purple sign group than in the no purple sign group (=0.0304).

Conclusions: The presence of purple sign indicates a lower risk of rebleeding after endoscopic treatment of cirrhotic gastroesophageal varices and a potentially favorable treatment response after endoscopic therapy, thus providing a clinical indicator for stratification of the patients for sequential endoscopic sessions.

References

Marques P, Maluf-Filho F, Kumar A, Matuguma S, Sakai P, Ishioka S . Long-term outcomes of acute gastric variceal bleeding in 48 patients following treatment with cyanoacrylate. Dig Dis Sci. 2007; 53(2):544-50. DOI: 10.1007/s10620-007-9882-5. View

Akahoshi T, Hashizume M, Shimabukuro R, Tanoue K, Tomikawa M, Okita K . Long-term results of endoscopic Histoacryl injection sclerotherapy for gastric variceal bleeding: a 10-year experience. Surgery. 2002; 131(1 Suppl):S176-81. DOI: 10.1067/msy.2002.119501. View

Seewald S, Ang T, Imazu H, Naga M, Omar S, Groth S . A standardized injection technique and regimen ensures success and safety of N-butyl-2-cyanoacrylate injection for the treatment of gastric fundal varices (with videos). Gastrointest Endosc. 2008; 68(3):447-54. DOI: 10.1016/j.gie.2008.02.050. View

Caldwell S, Hespenheide E, Greenwald B, Northup P, Patrie J . Enbucrilate for gastric varices: extended experience in 92 patients. Aliment Pharmacol Ther. 2007; 26(1):49-59. DOI: 10.1111/j.1365-2036.2007.03351.x. View

Zhou J, Wei Z, Sun Z . [Risk factors for early rebleeding after esophageal variceal ligation in patients with liver cirrhosis]. Zhonghua Gan Zang Bing Za Zhi. 2016; 24(7):486-492. DOI: 10.3760/cma.j.issn.1007-3418.2016.07.002. View

Abraldes J, Villanueva C, Banares R, Aracil C, Catalina M, Garci A-Pagan J . Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol. 2007; 48(2):229-36. DOI: 10.1016/j.jhep.2007.10.008. View

Wipassakornwarawuth S, Opasoh M, Ammaranun K, Janthawanit P . Rate and associated risk factors of rebleeding after endoscopic variceal band ligation. J Med Assoc Thai. 2002; 85(6):698-702. View

Zang L, Sun Z, Li W, Liu X . [Meta-analysis of risk factors of gastroesophageal varices rebleeding after therapeutic endoscopy]. Zhonghua Gan Zang Bing Za Zhi. 2015; 23(4):275-80. DOI: 10.3760/cma.j.issn.1007-3418.2015.04.009. View

Rajoriya N, Forrest E, Gray J, Stuart R, Carter R, McKay C . Long-term follow-up of endoscopic Histoacryl glue injection for the management of gastric variceal bleeding. QJM. 2010; 104(1):41-7. DOI: 10.1093/qjmed/hcq161. View

10.

Hung H, Chang C, Hou M, Liao W, Chan C, Huang H . Efficacy of non-selective β-blockers as adjunct to endoscopic prophylactic treatment for gastric variceal bleeding: a randomized controlled trial. J Hepatol. 2012; 56(5):1025-1032. DOI: 10.1016/j.jhep.2011.12.021. View

11.

Garcia-Tsao G, Abraldes J, Berzigotti A, Bosch J . Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2016; 65(1):310-335. DOI: 10.1002/hep.28906. View

12.

Lee H, Goh H, Kim T, Lee Y, Suh S, Jung Y . Evaluation of Treatment Response after Endoscopic Variceal Obturation with Abdominal Computed Tomography. Gut Liver. 2019; 14(1):117-124. PMC: 6974331. DOI: 10.5009/gnl18392. View

13.

Hou M, Lin H, Lee H, Liao W, Lee F, Lee S . A randomized trial of endoscopic cyanoacrylate injection for acute gastric variceal bleeding: 0.5 mL versus 1.0 mL. Gastrointest Endosc. 2009; 70(4):668-75. DOI: 10.1016/j.gie.2009.02.005. View

14.

Guo H, Zhang F, Yin X, Zhang M, Xiao J, Wang Y . Endoscopic therapy + β-blocker vs. covered transjugular intrahepatic portosystemic shunt for prevention of variceal rebleeding in cirrhotic patients with hepatic venous pressure gradient ≥16 mmHg. Eur J Gastroenterol Hepatol. 2020; 33(11):1427-1435. DOI: 10.1097/MEG.0000000000001872. View

15.

Lo G, Liang H, Chen W, Chen M, Lai K, Hsu P . A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy. 2007; 39(8):679-85. DOI: 10.1055/s-2007-966591. View

16.

Tan P, Hou M, Lin H, Liu T, Lee F, Chang F . A randomized trial of endoscopic treatment of acute gastric variceal hemorrhage: N-butyl-2-cyanoacrylate injection versus band ligation. Hepatology. 2006; 43(4):690-7. DOI: 10.1002/hep.21145. View

17.

Kang E, Jeong S, Jang J, Cho J, Lee S, Kim H . Long-term result of endoscopic Histoacryl (N-butyl-2-cyanoacrylate) injection for treatment of gastric varices. World J Gastroenterol. 2011; 17(11):1494-500. PMC: 3070025. DOI: 10.3748/wjg.v17.i11.1494. View

18.

Kageyama K, Nishida N, Yamamoto A, Jogo A, Hamamoto S, Matsui H . Risk factors for rebleeding and prognostic factors for postoperative survival in patients with balloon-occluded retrograde transvenous obliteration of acute gastric variceal rupture. Cardiovasc Intervent Radiol. 2014; 37(5):1235-42. DOI: 10.1007/s00270-013-0807-8. View

19.

Kovacs T, Jensen D . Varices: Esophageal, Gastric, and Rectal. Clin Liver Dis. 2019; 23(4):625-642. DOI: 10.1016/j.cld.2019.07.005. View